SBC Medical Group Holdings Incorporated

SBC Medical Group Holdings Incorporated (SBC) Market Cap

SBC Medical Group Holdings Incorporated has a market capitalization of $314.7M.

Price: $3.06

0.05 (1.66%)

Market Cap: 314.70M

NASDAQ · time unavailable

CEO: Yoshiyuki Aikawa

Sector: Industrials

Industry: Consulting Services

IPO Date: 2022-09-26

Website: https://sbc-holdings.com

SBC Medical Group Holdings Incorporated (SBC) - Company Information

Market Cap: 314.70M|Sector: Industrials

Company Profile

SBC Medical Group Holdings Incorporated provides management services to cosmetic treatment centers in Japan, Vietnam, the United States, and internationally. The company offers advertising and marketing services; staff management services, such as recruitment and training; booking reservations for franchisee clinic customers; assistance with franchisee employee housing rentals and facility rentals; construction and design of franchisee clinics; medical equipment; and medical consumables procurement. It provides IT software solutions; breast augmentation, liposuction, and rejuvenation treatments, including treatment of wrinkles, acne, scars, cellulite, excess fat, discoloration, and signs of aging; laser skin toning and spot removal; eyes double fold surgery; rhinoplasty; treatment of osmidrosis and hyperhidrosis; hair transplants; gynecological formation treatments; laser hair removal; face line surgeries; cosmetical dental procedures; tattoo removal; lasik eye surgery; lateral canthoplasty; brow lift procedures; androgenetic alopecia treatment; and cheek sagging prevention methods. The company was founded in 2000 and is headquartered in Irvine, California.

Analyst Sentiment

92%
Strong Buy

From 3 Active Polls

1Y Forecast: $12.00

▲ +292.2% Potential Upside

Consensus Target Metrics

Low Bound

$9

Median

$12

High Bound

$15

Average

$12

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$12.00
▲ +292.17% Upside
Low Target
$9.00
194% Risk
Median Target
$12.00
292% Mid
High Target
$15.00
390% Max
Consensus
Buy
1 / 1 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)3154294424454803295717581,231
Enterprise Value ($M)1682823303463432114586491,157
Price to Earnings Ratio (P/E)7.699.487.788.6848.843.8321.8466.8816.65
Price/Earnings-to-Growth Ratio (PEG)1.070.59
Price to Sales Ratio (P/S)1.869.9611.1710.2811.086.9612.8614.2823.18
Price to Book Ratio (P/B)1.231.681.781.801.961.452.933.707.68
Price to Free Cash Flow Ratio (P/FCF)7.1449.386.77-21.15-54.26280.71-72.37201.6467.16
Enterprise Value to Sales (EV/Sales)6.558.347.997.914.4710.3212.2221.79
Enterprise Value to EBITDA (EV/EBITDA)2.3615.3317.1017.9724.126.5965.4645.9141.43
Debt to Equity Ratio-2.060.080.210.110.060.060.060.140.18

SBC Growth Runway Model

Standard long term linear growth fade

Multi-Stage Discounted Cash Flow Sandbox

Market Price$3.06
Intrinsic Value$3.06
Market Alignment
Overvalued by 0.1%relative to calculated intrinsic value
9.00%
Exp: 1%1%
i

Growth runway slowdown

This value provides a time window for the growth rate to decline beyond Stage 1 toward the terminal rate. Longer windows are most useful for companies with high growth starting conditions or strong competitive advantages. This option stretches out the growth rate slowdown across 5, 10, or 15-year steps. A high-growth starting condition (exceeding a 25% initial growth rate) automatically applies a curve decay to simulate realistic, rapid market saturation.
i

Terminal growth rate

With long-term inflation between 3-5%, revenue must grow by that baseline to maintain flat real-world market share. This value sets the permanent terminal growth rate to factor into the valuation beyond the growth slowdown runway toward maturity.

3-Stage Financial Runway Horizon

🧠 Perpetuity Horizon Engine (Stage 3: Post-2035)

Terminal FCF Base$0.03B
Perpetuity TV Value$0.59B
Discounted TV (PV)$0.25B
TV Weighting %57.7%
⚠️
Financial Model Disclaimer & Risk Disclosure: This interactive scenario simulator is an educational sandbox provided strictly for informational and analytical research purposes. Core historical financial statements and consensus estimates are sourced directly via Financial Modeling Prep (FMP). All downstream outputs are entirely deterministic, hypothetical projections generated by combining automated mathematical formulas (including linear interpolation and Gaussian bell-curve decay models) with user-selected variables and third-party financial data inputs. Users assume all liability for trading decisions executed based on these sandbox calculations.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 SBC MEDICAL GROUP HOLDINGS INC (SBC) — Investment Overview

🧩 Business Model Overview

SBC Medical Group Holdings operates a network-based healthcare delivery model focused on outpatient and community-accessible medical services. The value chain centers on (1) acquiring and retaining patients through service accessibility and physician capability, (2) delivering medical encounters across multiple specialties (e.g., diagnostics, consultations, and procedure-based services depending on the clinic mix), and (3) converting patient flow into repeat visits through care pathways and follow-up treatment plans. The operating engine relies on clinic footprint planning, workforce productivity (physician and clinical staffing), and service mix management to translate demand into usable capacity. Patient retention and clinician relationships support stickiness in ongoing care rather than purely one-off encounters.

💰 Revenue Streams & Monetisation Model

Revenue is primarily generated from healthcare service delivery, typically comprising:
  • Procedure and service-based revenue: billed per encounter and often tied to case mix (complexity, specialty mix, and diagnostic/procedural components).
  • Consultation and follow-up visits: a source of recurring activity where clinical programs require periodic reassessment or monitoring (supporting steadier demand versus purely episodic care).
  • Diagnostics- and ancillary-linked revenue: where clinics bundle or coordinate diagnostic work with treatment, improving conversion from consults to billable services.
Margin drivers are largely operational: (1) physician productivity and utilization, (2) mix shift toward higher-acuity specialties and services with better gross margin characteristics, and (3) disciplined cost control across staffing, facility overhead, and supplier contracts. Because healthcare delivery is labor- and utilization-intensive, SBC’s economics depend on maintaining capacity efficiency and favorable service mix.

🧠 Competitive Advantages & Market Positioning

SBC’s moat is best characterized as an integrated clinical delivery ecosystem with operational switching costs rather than pure technology/IP superiority. Key advantages include:
  • High barriers to entry from licensure and execution: healthcare clinic networks face regulatory licensing requirements, facility standards, credentialing, and ongoing compliance costs that deter new entrants and slow replication of service capability.
  • Continuity of care creates patient-level switching costs: repeat visits, established medical histories, and clinician familiarity reduce friction for patients to remain within the same provider network for ongoing management.
  • Local operational scale: concentrated clinic operations improve scheduling efficiency, labor allocation, and procurement leverage versus smaller standalone operators.
  • Network effects at the clinical level (limited but real): a larger patient base supports fuller appointment books, which in turn helps retain clinical talent and improves service availability—further reinforcing demand.
Competitive benchmarking: SBC competes with other multi-site healthcare providers and clinic operators. Primary peer examples include:
  • Raffles Medical Group — a large, integrated provider with broad outpatient and hospital-adjacent capabilities.
  • IHH Healthcare — a diversified healthcare group with hospitals and regional care delivery scale.
  • Thomson Medical Group (clinic/hospital network) — competing for outpatient and specialist care demand through established facility presence.
Contrast in focus: SBC’s competitive positioning emphasizes scalable outpatient delivery and care continuity within its service footprint. Larger integrated hospital-centric operators may have advantages in referral networks and inpatient throughput, while smaller standalone clinics may face disadvantages in staffing depth, service mix, and capacity utilization.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, SBC’s growth opportunity is driven by secular demand and network execution:
  • Demographic shift and chronic disease prevalence: outpatient management and periodic monitoring increase the addressable volume of consults and follow-ups.
  • Rising preference for accessible outpatient care: patients often favor lower-friction, community-based delivery for consultations, diagnostics, and routine interventions.
  • Service mix expansion: adding or scaling higher-acuity specialties and procedure-based services can improve revenue per encounter and profitability.
  • Clinic footprint and capacity scaling: opening new sites or expanding existing clinics can convert demand into utilization, supporting operating leverage once ramp-up stabilizes.
  • Operational refinement: better scheduling, clinical pathways, and diagnostic-to-treatment conversion can lift productivity without requiring proportional increases in fixed costs.
Total addressable market expansion is supported less by pure market share gains and more by the structural growth of outpatient utilization and the shift toward organized provider networks.

⚠ Risk Factors to Monitor

  • Regulatory and compliance risk: healthcare delivery is governed by licensing, credentialing, data handling, and operational standards; changes can increase compliance cost or constrain expansion.
  • Workforce and wage pressure: physician and clinical staffing is central to service delivery economics; wage inflation or credential shortages can pressure margins.
  • Concentration risk in payer/patient sourcing: if demand is skewed toward specific channels or demographics, volume volatility can occur.
  • Reimbursement and pricing pressure: reimbursement dynamics and competitive pricing in outpatient settings can compress revenue per encounter.
  • Execution risk in expansions: new clinic ramps may face utilization delays, leading to higher fixed-cost absorption burdens before stabilization.
  • Technological and practice-pattern disruption: shifts in diagnostic modalities or care pathways may require investment in capabilities and training to maintain competitiveness.

📊 Valuation & Market View

Healthcare service providers are often valued using a combination of:
  • EV/EBITDA or EV/EBITDA-like multiples for operating leverage and margin durability
  • P/S when investor focus centers on revenue growth and network scaling
  • DCF-style frameworks for longer-duration cash-flow durability from recurring follow-up care and operational improvements
Key valuation drivers typically include sustainable clinic utilization, margin structure (labor productivity and service mix), and evidence that new sites can reach steady-state economics without impairing returns. Investor sentiment tends to strengthen when growth is accompanied by stable or improving unit economics rather than purely top-line expansion.

🔍 Investment Takeaway

SBC’s long-term thesis rests on an outpatient network model that benefits from regulatory barriers, continuity of care, and operational scale—forming switching costs for patients and practical impediments for new entrants. The investment case strengthens when SBC demonstrates the ability to scale clinic capacity, improve service mix, and maintain staffing productivity, converting demand into consistent utilization and durable profitability.

⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

14 Stories Available

Real-time institutional reporting and market updates for SBC.

globenewswire.com2026-05-26

SBC Medical will participate in several upcoming investor conferences in May and June 2026

IRVINE, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization providing management support across a wide range of healthcare fields, today announced its participation in several upcoming investor conferences in May and June 2026.

globenewswire.com2026-05-22

SBC Medical and BLEZ ASIA Celebrate Opening of New Aesthetic Dermatology Section at BLEZ CLINIC in Bangkok

Japanese-Quality Pico Laser Treatment to Serve the Growing Thai Aesthetic Healthcare Market, with Service Launch Scheduled for June 2026 Japanese-Quality Pico Laser Treatment to Serve the Growing Thai Aesthetic Healthcare Market, with Service Launch Scheduled for June 2026

accessnewswire.com2026-05-20

Emerging Growth Research Releases Q1:26 Quarterly Update on SBC Medical Group; Upgrades to Buy Rating and Increases Price Target to $10.00

NEW YORK CITY, NY / ACCESS Newswire / May 20, 2026 / Emerging Growth Research today announced the release of its Q1:26 Quarterly Update Report on SBC Medical Group Holdings, Inc. (NASDAQ:SBC), upgrading the Company to a Buy rating and increasing its 12-month price target to $10.00 from $9.00, representing significant potential upside from the Company's recent share price of $2.89 as of May 19, 2026. The Quarterly Update highlights SBC's expectation for a return to revenue growth in 2026 following the completion of pricing-related headwinds experienced during 2025, while emphasizing the Company's strong cash position, expanding clinic footprint, and long-term global growth strategy.

marketbeat.com2026-05-14

SBC Medical Group Q1 Earnings Call Highlights

SBC Medical Group NASDAQ: SBC reported first-quarter 2026 revenue of $43 million, down 9% from a year earlier, as management said prior fee structure revisions continued to weigh on reported results even as underlying clinic activity improved.

gurufocus.com2026-05-14

SBC Medical Group Holdings Announces First Quarter 2026 Financial Results

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization providing management support ac

businesswire.com2026-05-14

SBC Medical Group Holdings Announces First Quarter 2026 Financial Results

IRVINE, Calif.--(BUSINESS WIRE)-- #1Q--SBC Medical announce to first quarter financial results.

globenewswire.com2026-05-01

SBC Medical to Announce 1Q 2026 Financial Results

IRVINE, Calif., May 01, 2026 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization providing management support across a wide range of healthcare fields, today announced it will release its financial results for the first quarter ended March 31, 2026, before U.S. market open on May 14, 2026.

globenewswire.com2026-04-27

SBC Medical Announces Full-Scale Rollout of Aesthetic Healthcare-Focused Interpretation App "Talk Bridge" Across All Shonan Beauty Clinic Locations

IRVINE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ("SBC Medical" or the "Company"), a Medical Services Organization providing management support across a wide range of healthcare fields, today announced a comprehensive initiative to enhance English-speaking inbound customer support at Shonan Beauty Clinic.

defenseworld.net2026-04-27

SBC Medical Group (NASDAQ:SBC) and Selectis Health (OTCMKTS:GBCS) Head to Head Analysis

SBC Medical Group (NASDAQ: SBC - Get Free Report) and Selectis Health (OTCMKTS:GBCS - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations. Risk and Volatility SBC Medical Group

defenseworld.net2026-04-24

Analyzing SBC Medical Group (NASDAQ:SBC) and Solventum (NYSE:SOLV)

SBC Medical Group (NASDAQ: SBC - Get Free Report) and Solventum (NYSE: SOLV - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, profitability and earnings. Institutional and Insider Ownership 60.8% of SBC Medical

accessnewswire.com2026-04-22

Emerging Growth Research Releases Flash Report on SBC Medical Group; Reiterates Buy-Extended Rating and $9.00 Price Target

NEW YORK CITY, NY / ACCESS Newswire / April 22, 2026 / Emerging Growth Research today announced the release of a Flash Report on SBC Medical Group Holdings, Inc. (NASDAQ:SBC), reiterating its Buy-Extended rating and maintaining its 12-month price target of $9.00, representing potential upside from the Company's recent share price of $3.65 as of April 21, 2026. The Flash Report provides an update following recent share price volatility tied to a secondary share transaction, while reaffirming the Company's long-term growth outlook and underlying fundamentals.

businesswire.com2026-04-21

SBC Medical Announces Closing of Previously Announced Secondary Public Offering of 3.1 million shares of Common Stock

IRVINE, Calif.--(BUSINESS WIRE)-- #Healthcare--SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“the Company”), a Management Service Organization operating a wide range of franchise businesses across diverse medical fields, today announced the closing of its previously announced underwritten secondary public offering of 3,100,000 shares of the Company's common stock by Dr. Yoshiyuki Aikawa (the “Selling Stockholder”) at the public offering price of $3.25 per share. The proceeds from the offering to the.

businesswire.com2026-04-19

SBC Medical Announces Pricing of Secondary Public Offering of 3.1 Million Shares of Common Stock

IRVINE, Calif.--(BUSINESS WIRE)-- #Healthcare--SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“the Company”), a Management Service Organization operating a wide range of franchise businesses across diverse medical fields, today announced the pricing of the underwritten secondary public offering of 3,100,000 shares of the Company's common stock by Dr. Yoshiyuki Aikawa (the “Selling Stockholder”) at the public offering price of $3.25 per share. Additionally, the Selling Stockholder has granted the unde.

accessnewswire.com2026-04-06

Emerging Growth Research Reiterates Buy-Extended Rating on SBC Medical Group Holdings, Inc. with $9.00 Price Target Following Q4:25 Quarterly Update

NEW YORK CITY, NY / ACCESS Newswire / April 6, 2026 / Emerging Growth Research today announced the release of its Quarterly Update Report on SBC Medical Group Holdings, Inc. (Nasdaq:SBC), reiterating a Buy-Extended rating and maintaining its 12-month price target of $9.00, representing potential upside from the Company's closing price of $4.47 on April 3, 2026. The Quarterly Update reflects SBC's Q4:25 financial results, ongoing business transition, and outlook for a return to revenue growth in 2026 following pricing-related headwinds experienced during 2025.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"SBC reported Q1 2026 revenue of $37.95M and net income of $11.31M (EPS $0.11). On a YoY basis (vs Q1 2025), revenue declined (37.95M vs 47.33M = -19.8%), while net income also fell materially (11.31M vs 21.50M = -47.4%). QoQ, revenue edged down from Q4 2025 ($39.57M to $37.95M = -4.1%) and net income declined ($14.20M to $11.31M = -20.4%). Profitability was mixed over the last four quarters: gross margin improved from Q4’s 73.1% to 80.0% in Q1 2026, and operating margin rose to 46.7% (up sharply from Q4’s 32.5%). However, net margin compressed versus Q4 (29.8% in Q1 vs 35.9% in Q4) and remains below the very strong Q1 2025 level (45.4%). Cash flow quality is solid in the most recent quarter: operating cash flow was $9.23M and free cash flow was $9.11M, with $0 dividends and no buybacks reported. Balance sheet resilience appears strong: total assets were $388.0M with equity of $270.4M, and net debt is negative (net cash position improved further to about -$146.9M). From a shareholder-return standpoint, the stock’s 1Y change is only +1.13% (below the >20% momentum threshold), and with a 0% dividend yield reported, total shareholder return is currently driven mainly by price appreciation rather than income."

Revenue Growth

Caution

Revenue fell YoY by -19.8% (Q1 2025 $47.33M to Q1 2026 $37.95M) and declined QoQ by -4.1% ($39.57M to $37.95M). The trajectory over the last four quarters shows weaker top-line consistency, with Q1 2026 below Q2/Q3/Q1 2025 levels.

Profitability

Neutral

Gross margin improved to 80.0% in Q1 2026 from 73.1% in Q4 2025. Operating margin also improved to 46.7% (from 32.5%). Despite this, net margin compressed vs Q4 (29.8% vs 35.9%) and net income was down YoY (-47.4%) and QoQ (-20.4%).

Cash Flow Quality

Positive

Q1 2026 generated operating cash flow of $9.23M and free cash flow of $9.11M, indicating positive conversion of earnings. Dividends paid were $0 and no repurchases were reported in the quarter.

Leverage & Balance Sheet

Strong

Balance sheet remains very liquid and low leverage: total assets increased to $388.0M with equity of $270.4M. Net debt is strongly negative (net cash) at about -$146.9M in Q1 2026, improving from -$112.1M in Q4 2025.

Shareholder Returns

Fair

Reported dividend yield is 0%. Price momentum is modest: +1.13% over 1Y, which does not meet the >20% momentum threshold. With limited evidence of buybacks, total shareholder returns appear muted.

Analyst Sentiment & Valuation

Positive

Consensus price target is $12 (median), vs current price $4.49, implying substantial upside on the target set. However, the realized fundamental trend shows declining YoY net income, so valuation optimism may carry execution risk.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for SBC.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (SBC)

© 2026 Stock Market Info — SBC Medical Group Holdings Incorporated (SBC) Financial Profile